Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its supplemental biologics license application (sBLA) for Breyanzi (lisocabtagene maraleucel). The sBLA is for expanding the current indication of the CD19-directed chimeric antigen receptor (CAR) T cell therapy to be used in the treatment of relapsed or refractory […]
Zai Lab Limited said that it has treated the first patient in Greater China in the PANOVA-3 phase 3 clinical trial of tumor treating fields (TTFields) in pancreatic cancer. Tumor Treating Fields are electric fields which disrupt cancer cell division. PANOVA-3 is a global, open-label, randomized late-stage trial for assessing the efficacy of Tumor Treating […]
Labcorp, a North Carolina-based life sciences company, has agreed to acquire Personal Genome Diagnostics (PGDx), a provider of liquid biopsy and tissue-based genomic products and services, in a deal worth up to $575 million. According to Labcorp, the Maryland-based Personal Genome Diagnostics alongside its technology complements and expedites its existing liquid biopsy capabilities and grows […]
Sun Pharma Advanced Research Company (SPARC) has signed an agreement with US-based Biomodifying for the exclusive licensing of the latter’s intellectual property (IP), including all patents and patent applications owned or controlled by it in addition to antibodies developed for various uses including for cancer. The India-based clinical stage biopharma company, which is owned by […]
Zydus Cadila has secured final approval from the US Food and Drug Administration (FDA) for the commercialization of the cancer medication Decitabine for Injection in the strength of 50mg/vial Single-Dose Vial. Decitabine for Injection is a generic of Dacogen, which is approved for the treatment of myelodysplastic syndromes, some types of blood or bone marrow […]
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier this month by the Indian pharma company’s Canadian subsidiary — Natco Pharma (Canada). PrNAT-LENADLIDOMIDE in combination with dexamethasone is approved by Health Canada for the treatment of multiple myeloma in […]
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric cancer. Enhertu is a HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo. According to AstraZeneca, the antibody drug conjugate delivered the desired tumor response in patients suffering […]
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral injection in phase 2 clinical trials both in China and the US. According to the Chinese pharma company, the US phase 2a portion of the study has two parts, of which the first is the evaluation of […]
Swiss healthcare company Roche has launched the Elecsys Anti-p53 immunoassay to help in the diagnosis of various types of cancer by the in vitro quantitative determination of anti-p53 antibodies. The Anti-p53 immunoassay test will help physicians in diagnosing oesophageal cancer, breast cancer, and bowel cancer in patients, in combination with other diagnostic tests, said Roche. […]
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]